GlycoBac announces partnership with MilliporeSigma

GlycoBac has partnered with MilliporeSigma to facilitate the distribution of our Sf-RVN cell line for commercial vaccine and gene therapy vector production. In addition to distributing Sf-RVN cells through a cGMP cell bank, MilliporeSigma will offer a chemically defined medium formulation specially designed for Sf-RVN cells. See the announcement from MilliporeSigma

GlycoBac has been featured in several media reports:

(University of Wyoming, April 1 2014)

(Wyoming business report, October 18, 2012)

(Casper star Tribune, April 22 2012)

UW Professor’s Company, UW Sign Agreement to Commercialize Research 

GlycoBac on KCWY13